IL6 and systemic-onset juvenile idiopathic arthritis: The American College of Rheumatology response criteria and the Juvenile Arthritis Disease Activity Score based on 10 joints (JADAS-10) established that etanercept is less effective in children with sJIA compared to IL-6 or IL-1 blockers [59,60].